Form 4: ANI Pharmaceuticals Executive Sells Shares Under 10b5-1 Trading Plan

Meredith Cook, Senior VP, General Counsel & Secretary of ANI Pharmaceuticals, sold 250 shares of common stock at $61.36 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Meredith Cook, a Senior VP, General Counsel & Secretary at ANI Pharmaceuticals, sold 250 shares of the company's common stock.
• The transaction occurred on November 13, 2024, at a price of $61.36 per share.
• This sale was executed under a pre-existing Rule 10b5-1 trading plan adopted on August 11, 2023.
• Following the transaction, Ms. Cook directly owns 56,238 shares of ANI Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an executive stock sale under a pre-arranged plan. It does not indicate any positive or negative sentiment.

Industry Context

This is a routine filing related to insider trading activity. It is common for executives to use 10b5-1 plans to manage their stock sales and avoid accusations of trading on inside information.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a standard practice among corporate executives to manage their stock sales.
• The reported transaction is consistent with typical insider trading disclosures.
• Similar filings are regularly made by executives at other pharmaceutical companies such as Teva Pharmaceuticals and Mylan.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on shareholder sentiment, but is unlikely to have a significant effect due to the pre-arranged nature of the transaction.

Key Dates

Keywords

ANI Pharmaceuticals, insider trading, Form 4, stock sale, Rule 10b5-1, Meredith Cook, executive transaction